Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-09-20
Based on 131 first isolates · ICU · Skin / wound infection · 2025-09-21 → 2026-09-20
Intensive care unit
Per-organism detail: ICU wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 55 % (46 %–63 %)
Best two-drug combination: vancomycin + meropenem covers 98 % (95 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (14 %), Escherichia coli (13 %), Klebsiella pneumoniae (9 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
55 %
60 %
n = 10
meropenem MEM
trend · Pseudomonas aeruginosa reserve
44 %
40 %
n = 10
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
43 %
40 %
n = 10
42 %
40 %
n = 10
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
42 %
50 %
n = 10
29 %
30 %
n = 10
ceftriaxone CRO
trend · Escherichia coli
28 %
20 %
n = 10
19 %
0 %
n = 10
12 %
10 %
n = 10
mecillinam MEC
not for this site
0 %
0 %
n = 10
trimethoprim TMP
not for this site
0 %
0 %
n = 10
nitrofurantoin NIT
not for this site
0 %
0 %
n = 10

Most likely organisms for this profile

Staphylococcus aureus
50 %
Pseudomonas aeruginosa
14 %
Escherichia coli
13 %
Klebsiella pneumoniae
9 %
Proteus mirabilis
8 %
Enterococcus faecalis
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.